

Disclosure in respect of Employee Stock Option Scheme set-up with approval of the members of the Company granted at extra ordinary general meeting held on 18-3-2004* ('the said old scheme") required in terms of SEBI Circular CIR/CFD/POLICY CELL/2/2015 dated June 16, 2015 for the year ended on March 31, 2021.

Sr. No.	Requirement	Disclosure			
A.	Relevant disclosures in terms of the 'Guidance note on accounting for employee share-based payments' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	There were no options granted/vested/			
В.	Diluted EPS on issue of shares pursuant to all the schemes covered under the regulations shall be disclosed in accordance with 'Accounting Standard 20 - Earnings Per Share' issued by ICAI or any other relevant accounting standards as prescribed from time to time.	No shares has been issued during the year.			
C.	Details related to ESOS				
	(i) A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including –				
	(a) Date of shareholders' approval	18-03-2004			
	(b) Total number of options approved under ESOS	25,00,000 equity shares of face value Rs. 2.			
	(c) Vesting requirements	The options granted were to vest after a period of twelve months from the date of grant in accordance with the following schedule:			
		No. of months next following the end of calendar month in which date of grant falls Percentage of the total options that would get vested in the employee on the expiry of period mentioned in Col. No.1			

Neelam Centre, B Wing, 4th Floor Hind Cycle Road Worli, Mumbai - 400 030

Ocrporate Office:

Cnergy IT Park Unit A2, 3rd Floor, Unit A, 8th Floor Appa Saheb Marathe Marg, Prabhadevi Mumbai - 400 025 +91 22 2439 5200

A +91 22 2431 5331 / 533

@ info@jbcpl.com

@ into@jbcpi.com

CIN: L24390MH1976PLC019380



	End of 12 25% months
	End of 24 25% months
	End of 36 25% months
	End of 48 25% months
	Special provisions for vesting of options in case of resignation, dismissal/ discharge, retirement, death and total permanent disability of an employee.
(d) Exercise price or pricing formula	Exercise price was to be an amount equal to 95% of the average of the closing price of the shares of the Company quoted on National Stock Exchange during the period of 12 weeks preceding the date of grant. If price so determined contained a part of Rupee consisting of paise, then the exercise price was to be rounded-off to the next Rupee.
(e) Maximum term of options granted	As above
(f) Source of shares (primary, secondary or combination)	Primary
(g) Variation in terms of options	Not Applicable
(ii) Method used to account for ESOS - Intrinsic or fair value.	Fair Value
(iii) Where the company opts for expensing of the options using the intrinsic value of the options, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options shall be disclosed. The impact of this	Not applicable
difference on profits and on EPS of the company shall also be disclosed.	S PHARM S MAUMBA

Hind Cycle Road Worli, Mumbai - 400 030

CIN: L24390MH1976PLC019380

^{4 +91 22 2431 5331 / 5334}

[@] info@jbcpl.com

[@] www.jbcpl.com



	Particulars		Details	
	Number of options outstanding at the beg	Nil		
	Number of options granted during the year	ar	Nil	
	Number of options forfeited / lapsed duri	ng the year	Nil	
	Number of options vested during the yea	r	Nil Nil	
	Number of options exercised during the	year		
	Number of shares arising as a result of exercise of options		Nil	
	Money realized by exercise of options (INR), if scheme is implemented directly by the company		Nil	
	Loan repaid by the Trust during the year from exercise price received		Not applicab	
	Number of options outstanding at the end	of the year	Nil	
	Number of options exercisable at the end	of the year	Nil	
(vi)	Employee wise details (name of employee, designation, number of options granted during the year, exercise price) of options granted to- Senior managerial personnel;	Not applicable		
	1	No options were granted during the year.		
b)	grant in any one year of option	Not applicable No options were granted during the year.		
c)	granted option, during any one year,	Not applicable No options were granted during the year.		

^{🚇 +91 22 2431 5331 / 5334}

[@] info@jbcpl.com

[@] www.jbcpl.com



(vii)	A descr	ription of	f the	method	and
	significant assumptions used during				
	the year	to estima	ite the	fair val	ue of
	options	includir	ig th	e follo	wing
	informat	ion:	_		_

- the weighted-average values of share price, exercise price, expected volatility, expected option life, expected dividends, the risk-free interest rate and any other inputs to the model;
- the method used and the assumptions made to incorporate the effects of expected early exercise;
- how expected volatility was determined, including an explanation of the extent to which expected volatility was based on historical volatility; and
- d) whether and how any other features of the option grant were incorporated into the measurement of fair value, such as a market condition.

Not Applicable

Place: Mumbai Date: 14-6-2021 For J. B. CHEMICAL & PHARMACEUTICALS LTD.

Company Secretary & Vice President-Compliance

^{4 +91 22 2431 5331 / 5334}

[@] info@jbcpl.com

[@] www.jbcpl.com